159 related articles for article (PubMed ID: 37582673)
1. SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: Meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type.
Bechmann LE; Emanuelsson F; Nordestgaard BG; Benn M
Atherosclerosis; 2024 Jul; 394():117236. PubMed ID: 37582673
[TBL] [Abstract][Full Text] [Related]
2. Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: A systematic review and meta-analysis of 48 randomized controlled trials.
Sánchez-García A; Simental-Mendía M; Millán-Alanís JM; Simental-Mendía LE
Pharmacol Res; 2020 Oct; 160():105068. PubMed ID: 32652200
[TBL] [Abstract][Full Text] [Related]
3. Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.
Blais JE; Huang X; Zhao JV
Drugs; 2023 Apr; 83(5):403-427. PubMed ID: 36941490
[TBL] [Abstract][Full Text] [Related]
4. Lipid control and use of lipid-regulating drugs for prevention of cardiovascular events in Chinese type 2 diabetic patients: a prospective cohort study.
Ting RZ; Yang X; Yu LW; Luk AO; Kong AP; Tong PC; So WY; Chan JC; Ma RC
Cardiovasc Diabetol; 2010 Nov; 9():77. PubMed ID: 21092182
[TBL] [Abstract][Full Text] [Related]
5. Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON.
Lorenzatti AJ; Monsalvo ML; López JAG; Wang H; Rosenson RS
Cardiovasc Diabetol; 2021 Apr; 20(1):94. PubMed ID: 33941192
[TBL] [Abstract][Full Text] [Related]
6. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
[TBL] [Abstract][Full Text] [Related]
7. Non-HDL cholesterol goal attainment and its relationship with triglyceride concentrations among diabetic subjects with cardiovascular disease: A nationwide survey of 2674 individuals in Hungary.
Mark L; Vallejo-Vaz AJ; Reiber I; Paragh G; Kondapally Seshasai SR; Ray KK
Atherosclerosis; 2015 Jul; 241(1):62-8. PubMed ID: 25966441
[TBL] [Abstract][Full Text] [Related]
8. The effect of a dual combination of noninsulin antidiabetic drugs on lipids: a systematic review and network meta-analysis.
Dai X; Wang H; Jing Z; Fu P
Curr Med Res Opin; 2014 Sep; 30(9):1777-86. PubMed ID: 24805140
[TBL] [Abstract][Full Text] [Related]
9. Effect of Fructose on Established Lipid Targets: A Systematic Review and Meta-Analysis of Controlled Feeding Trials.
Chiavaroli L; de Souza RJ; Ha V; Cozma AI; Mirrahimi A; Wang DD; Yu M; Carleton AJ; Di Buono M; Jenkins AL; Leiter LA; Wolever TM; Beyene J; Kendall CW; Jenkins DJ; Sievenpiper JL
J Am Heart Assoc; 2015 Sep; 4(9):e001700. PubMed ID: 26358358
[TBL] [Abstract][Full Text] [Related]
10. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.
Teo YH; Teo YN; Syn NL; Kow CS; Yoong CSY; Tan BYQ; Yeo TC; Lee CH; Lin W; Sia CH
J Am Heart Assoc; 2021 Feb; 10(5):e019463. PubMed ID: 33625242
[TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD.
Lamprea-Montealegre JA; Staplin N; Herrington WG; Haynes R; Emberson J; Baigent C; de Boer IH;
Clin J Am Soc Nephrol; 2020 Jan; 15(1):47-60. PubMed ID: 31831577
[TBL] [Abstract][Full Text] [Related]
12. Impact of Lipid-Lowering Therapy on Mortality According to the Baseline Non-HDL Cholesterol Level: A Meta-Analysis.
Masson W; Lobo M; Siniawski D; Molinero G; Huerín M; Nogueira JP
High Blood Press Cardiovasc Prev; 2019 Aug; 26(4):263-272. PubMed ID: 31313082
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials.
Ju J; Li J; Lin Q; Xu H
Phytomedicine; 2018 Nov; 50():25-34. PubMed ID: 30466986
[TBL] [Abstract][Full Text] [Related]
14. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol.
Colhoun HM; Leiter LA; Müller-Wieland D; Cariou B; Ray KK; Tinahones FJ; Domenger C; Letierce A; Israel M; Samuel R; Del Prato S
Cardiovasc Diabetol; 2020 Feb; 19(1):14. PubMed ID: 32035487
[TBL] [Abstract][Full Text] [Related]
15. Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients.
Mazidi M; Rezaie P; Gao HK; Kengne AP
J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28546454
[TBL] [Abstract][Full Text] [Related]
16. HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes.
Sharif S; van der Graaf Y; Nathoe HM; de Valk HW; Visseren FL; Westerink J;
Diabetes Care; 2016 Aug; 39(8):1424-30. PubMed ID: 27222511
[TBL] [Abstract][Full Text] [Related]
17. Total red meat intake of ≥0.5 servings/d does not negatively influence cardiovascular disease risk factors: a systemically searched meta-analysis of randomized controlled trials.
O'Connor LE; Kim JE; Campbell WW
Am J Clin Nutr; 2017 Jan; 105(1):57-69. PubMed ID: 27881394
[TBL] [Abstract][Full Text] [Related]
18. Effects of sodium glucose cotransporter 2 inhibitors on risk of dyslipidemia among patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Li D; Wu T; Wang T; Wei H; Wang A; Tang H; Song Y
Pharmacoepidemiol Drug Saf; 2020 May; 29(5):582-590. PubMed ID: 32124527
[TBL] [Abstract][Full Text] [Related]
19. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
[TBL] [Abstract][Full Text] [Related]
20. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
